Although tolvaptan bests fluid restriction at raising plasma sodium concentration, 19% of patients experience overcorrection ...

Day One Biopharmaceuticals (NASDAQ:DAWN) executives highlighted accelerating commercial momentum for OJEMDA and outlined ...

Words like “trauma,” “narcissist,” and “anxious attachment” are now common currency. What happens when the language of psychology and psychiatry becomes the language of the everyday?

Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were ...

Incyte INCY recently announced that the European Commission has approved a label expansion of oncology drug Zynyz ...

European Commission approval enables 2 mg/kg Q4W pegunigalsidase alfa for stable, ERT-treated adults, extending infusion intervals from Q2W to Q4W to lessen cumulative treatment burden. Evidence ...

Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time ...

I was scrolling through my feed this morning and nearly did a double-take at the latest photos of Katy Perry. You know that ...

Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer.

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...

The next wave will focus on maintaining the skin in a constant state of resilience and repair readiness, writes Kristal ...